Get the Stockscreener App
19.10
3.14%
-0.62
After Hours:
19.15
0.05
+0.26%
Caredx Inc stock is traded at $19.10, with a volume of 647.32K.
It is down -3.14% in the last 24 hours and down -7.15% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$19.72
Open:
$20.1
24h Volume:
647.32K
Relative Volume:
0.83
Market Cap:
$982.36M
Revenue:
$312.78M
Net Income/Loss:
$-143.56M
P/E Ratio:
-7.1004
EPS:
-2.69
Net Cash Flow:
$1.22M
1W Performance:
+4.09%
1M Performance:
-7.15%
6M Performance:
+53.29%
1Y Performance:
-20.28%
1-Day Range:
$18.81
$20.29
1-Week Range:
$18.41
$21.00
52-Week Range:
$10.96
$25.55
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
19.10 | 1.01B | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-26-25 | Initiated | William Blair | Mkt Perform |
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy - The AI Journal
CareDx, Inc. $CDNA Stock Holdings Lessened by New York State Common Retirement Fund - MarketBeat
US Market Wrap: Whats the RSI of CareDx Inc stockJuly 2025 Movers & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Business Wire
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Trends: What is the dividend yield of CareDx IncJuly 2025 Patterns & AI Enhanced Trading Alerts - baoquankhu1.vn
Liquidity Mapping Around (CDNA) Price Events - Stock Traders Daily
CareDx (NASDAQ:CDNA) Cut to "Hold" at Wall Street Zen - MarketBeat
Can CareDx (CDNA) Turn AlloHeme’s ACROBAT Data Into a Durable Precision-Transplant Moat? - simplywall.st
Lobbying Update: $15,000 of CAREDX lobbying was just disclosed - Quiver Quantitative
Short Covering: Can CareDx Inc keep up with sector leadersChart Signals & Free Reliable Trade Execution Plans - baoquankhu1.vn
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - BioSpace
Momentum Shift: Will CareDx Inc stock benefit from M AWeekly Trend Summary & Reliable Volume Spike Alerts - baoquankhu1.vn
RSI Check: Will First Busey Corporation outperform small cap indexes2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Downgrade Watch: Will Quanex Building Products Corporation benefit from sector rotationMarket Risk Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Price Action: Does FDMT align with a passive investing strategyMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
CareDx CEO Sells Nearly 20,000 Shares in Open Market Transactions - Intellectia AI
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 - Yahoo Finance
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 - The Motley Fool
Did Strong 2025 Revenue Growth and 10x Genomics Deal Just Shift CareDx's (CDNA) Investment Narrative? - Yahoo Finance
CareDx President and CEO Sells 19,000 Shares for $412,000 - The Globe and Mail
CareDx, Inc. $CDNA is Gagnon Advisors LLC's 8th Largest Position - MarketBeat
CareDx, Inc. $CDNA Position Increased by Gagnon Securities LLC - MarketBeat
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Chartmill
Can CareDx Inc deliver consistent dividendsDollar Strength & Advanced Swing Trade Entry Alerts - mfd.ru
Death Cross: Is CareDx Inc a play on infrastructure spendingCPI Data & AI Based Buy and Sell Signals - baoquankhu1.vn
Aug Update: Can CareDx Inc beat the S P 5002025 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Is CareDx’s Upgraded 2025 Revenue Outlook Altering The Investment Case For CareDx (CDNA)? - Sahm
CareDx CEO Hanna sells $412,222 in shares By Investing.com - Investing.com UK
CareDx CEO Hanna sells $412,222 in shares - Investing.com
Insider Sell: Hanna John Walter JR Sells Shares of CareDx Inc (C - GuruFocus
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 19,280 Shares - MarketBeat
CareDx, Inc. (CDNA) Stock Analysis: A Healthcare Innovator With 4.66% Upside Potential - DirectorsTalk Interviews
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 10,156 Shares - MarketBeat
Tech Rally: What is the dividend yield of CareDx IncJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Sentiment Review: Can CareDx Inc generate free cash flow2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in CareDx, Inc. $CDNA - MarketBeat
CareDx (CDNA) Is Up 19.5% After Stronger-Than-Expected 2025 Revenue GuidanceHas The Bull Case Changed? - Sahm
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
CareDx (CDNA) Valuation Check After Strong Preliminary 2025 Revenue Guidance And Transplant+ Pipeline Progress - Sahm
Can CareDx Inc maintain sales growthJuly 2025 Short Interest & Expert Curated Trade Setups - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA) - The Globe and Mail
Implied Volatility Surging for CareDx Stock Options - sharewise.com
CareDx (CDNA) Is Up 9.4% After Strong 2025 Outlook And 10x Genomics Tie-UpHas The Bull Case Changed? - Yahoo Finance
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025 - Investing.com Canada
CareDx (NASDAQ:CDNA) Trading 15.3% HigherTime to Buy? - MarketBeat
Caredx Provides Earnings Guidance Fourth Quarter and Full Year 2025 - marketscreener.com
Aug Wrap: Is CareDx Inc a play on infrastructure spendingStop Loss & Weekly High Return Stock Forecasts - baoquankhu1.vn
CareDx Preliminary Q4 Revenue Up 25% - Nasdaq
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025 By Investing.com - Investing.com South Africa
CareDx's prelim Q4 revenue beats estimates on higher testing volumes - TradingView — Track All Markets
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):